Pricing Log in Create free account

InterCure Ltd. (INCR) vs Zhengye Biotechnology Holding Limited (ZYBT)

InterCure Ltd. and Zhengye Biotechnology Holding Limited are both Drug Manufacturers Specialty & Generic companies. InterCure Ltd. is the larger, with a market value of $55.1M against $44.6M — 1.2× the size. Across the 5 metrics below, InterCure Ltd. leads on 3 and Zhengye Biotechnology Holding Limited on 2.

Valuation

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
P/E 8.80 — 19.25
P/S 0.33 — 2.11
P/B 0.33 n/m 1.78
Price to free cash flow n/m n/m 16.14
EV/EBITDA 7.24 n/m 12.58
EV/Sales 0.66 n/m 2.73
Earnings yield 11.36% — (4.38%)
Free cash flow yield (2.02%) 0.00% 0.00%

Profitability

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Gross margin 32.74% — 53.94%
Operating margin 0.00% — 0.00%
Net margin 4.88% — 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 0.00% (0.40%)
Return on assets 0.00% 0.00% (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 16.15% — 10.01%
EPS growth (last fiscal year) 52.50% (800.00%) 49.06%
Revenue growth, 5-year CAGR 31.11% — 6.74%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Debt to equity 0.27 0.24 0.05
Current ratio 1.85 1.14 2.31
Net debt to EBITDA (4.07) (0.51) 0.97

Dividend

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric INCR ZYBT Drug Manufacturers Specialty & Generic median
Market cap 55.10m 44.59m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack